- Trials with a EudraCT protocol (15)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
15 result(s) found for: Brigatinib.
Displaying page 1 of 1.
EudraCT Number: 2019-002369-36 | Sponsor Protocol Number: GECP19/01 | Start Date*: 2020-04-18 | |||||||||||
Sponsor Name:Fundación GECP | |||||||||||||
Full Title: Clinical Utility of Liquid Biopsy as a tool to assess the evolution of brigatinib treated patients with non-small cell lung cancer with EML4-ALK translocation: an exploratory study | |||||||||||||
Medical condition: ALK+ non-small cell lung cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003447-19 | Sponsor Protocol Number: AP26113-13-301 | Start Date*: 2016-06-13 | |||||||||||
Sponsor Name:ARIAD Pharmaceuticals, Inc. (a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited) | |||||||||||||
Full Title: A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) versus Crizotinib in Patients with ALK-positive Advanced Lung Cancer | |||||||||||||
Medical condition: ALK positive Locally Advanced or Metastatic Non-small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) AT (Completed) DE (Completed) NL (Completed) FI (Completed) SE (Completed) NO (Completed) DK (Completed) ES (Completed) CZ (Prematurely Ended) PT (Completed) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-002713-34 | Sponsor Protocol Number: ITCC-098 | Start Date*: 2021-12-30 |
Sponsor Name:Princess Maxima Center for Pediatric Oncology in The Netherlands | ||
Full Title: A Phase I/II study of Brigatinib in pediatric and young adult patients with ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or other solid tumors | ||
Medical condition: relapsed/refractory ALK rearranged** or ALK mutated tumors, including relapsed/refractory ALK+ALCL and ALK+IMT. | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) DK (Trial now transitioned) SE (Trial now transitioned) IT (Trial now transitioned) DE (Trial now transitioned) NO (Prematurely Ended) BE (Trial now transitioned) FI (Trial now transitioned) PL (Trial now transitioned) AT (Ongoing) CZ (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2018-001957-29 | Sponsor Protocol Number: Brigatinib-3001 | Start Date*: 2018-12-13 | |||||||||||
Sponsor Name:ARIAD Pharmaceuticals, Inc.(a wholly-owned subsidiary of Takeda Pharmaceutical Ltd.) | |||||||||||||
Full Title: A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIGTM) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive on–Small-Cell Lung Cancer Patients Who Have Progresse... | |||||||||||||
Medical condition: ALK positive Locally Advanced or Metastatic Non-small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) SE (Completed) ES (Prematurely Ended) DE (Prematurely Ended) AT (Completed) GR (Prematurely Ended) HR (Completed) IT (Prematurely Ended) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000635-27 | Sponsor Protocol Number: 2002 | Start Date*: 2018-10-10 | |||||||||||
Sponsor Name:ARIAD Pharmaceuticals, Inc.(a wholly-owned subsidiary of Takeda Pharmaceutical Ltd.) | |||||||||||||
Full Title: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non–Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib | |||||||||||||
Medical condition: Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non–Small-Cell Lung Cancer (NSCLC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) DE (Completed) ES (Completed) AT (Completed) NL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-002567-22 | Sponsor Protocol Number: IFCT-2101 | Start Date*: 2022-01-10 | ||||||||||||||||
Sponsor Name:IFCT | ||||||||||||||||||
Full Title: A phase II randomized, open-labelled, multicenter study of safety and efficacy of combination brigatinib and carboplatin-pemetrexed therapy or brigatinib monotherapy as first-line treatment in pati... | ||||||||||||||||||
Medical condition: Advanced ALK-positive non-small cell lung cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-002134-21 | Sponsor Protocol Number: AP26113-13-201 | Start Date*: 2014-07-22 | |||||||||||
Sponsor Name:ARIAD Pharmaceuticals, Inc. (a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited) | |||||||||||||
Full Title: A Randomized Phase 2 Study of AP26113 in Patients with ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated with Crizotinib | |||||||||||||
Medical condition: Patients with ALK-positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) IT (Completed) NL (Completed) DK (Completed) AT (Completed) BE (Completed) SE (Completed) NO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004070-26 | Sponsor Protocol Number: BRICE | Start Date*: 2021-08-02 | |||||||||||
Sponsor Name:FONDAZIONE RICERCA TRASLAZIONALE (FORT) | |||||||||||||
Full Title: A Phase 1/2 Study Exploring Safety, Tolerability and Efficacy of BRIgatinib in Combination With CEtuximab in Subjects With Advanced EGFR mutated or ALK or ROS1 positive Non-Small Cell Lung Cancer a... | |||||||||||||
Medical condition: Advanced or metastatic epidermal growth factor receptor (EGFR) mutation positive non-small cell lung cancer (NSCLC) with acquired resistance to approved EGFR tyrosine kinase inhibitors (TKI); advan... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001828-36 | Sponsor Protocol Number: ABP-2019 | Start Date*: 2020-02-21 | |||||||||||
Sponsor Name:Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest | |||||||||||||
Full Title: Advancing Brigatinib Properties in anaplastic lymphoma kinase positive non-small cell lung cancer (ALK+ NSCLC) patients by deep phenotyping | |||||||||||||
Medical condition: Anaplastic lymphoma kinase positive non-small cell lung cancer (ALK+ NSCLC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002230-37 | Sponsor Protocol Number: IFCT-1902 | Start Date*: 2019-09-16 | ||||||||||||||||
Sponsor Name:IFCT | ||||||||||||||||||
Full Title: A phase II non-randomized, single group assignment, open-label, multicenter study of efficacy and safety of lORlatinib (PF-06463922) monotherapy after failure of first-line second-generation ALK ki... | ||||||||||||||||||
Medical condition: advanced ALK-positive non-small cell Lung cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000122-21 | Sponsor Protocol Number: NVL-655-01 | Start Date*: 2022-07-08 |
Sponsor Name:Nuvalent, Inc. | ||
Full Title: A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients with Advanced NSCLC and Other Solid Tumors (ALKOVE-1) | ||
Medical condition: Advanced Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors with ALK rearrangement or activating ALK mutation. | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) ES (Ongoing) DE (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2018-002190-21 | Sponsor Protocol Number: MAR-BAS-18-005 | Start Date*: 2020-07-08 | |||||||||||||||||||||
Sponsor Name:Fondazione per la Medicina Personalizzata | |||||||||||||||||||||||
Full Title: The ROME trial from histology to target: the road to personalize target therapy and immunotherapy | |||||||||||||||||||||||
Medical condition: Patients with progressive disease (recurrent and/or metastatic) of breast cancer, metastatic gastro-intestinal tumors, non small cell lung cancer (NSCLC) or others. Patients should have completed a... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003954-26 | Sponsor Protocol Number: STAR22 | Start Date*: 2019-01-30 |
Sponsor Name:Erasmus MC Cancer Institute | ||
Full Title: CYP3A4*22 genotype-guided dosing of TKIs in cancer patients: a new way of personalized therapy | ||
Medical condition: Patients diagnosed with a neoplasm and treated with a tyrosine kinase inhibitor which is mainly metabolised by CYP3A4. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2016-003616-13 | Sponsor Protocol Number: TPX-0005-01 | Start Date*: 2020-05-12 | |||||||||||
Sponsor Name:Turning Point Therapeutics, Inc. | |||||||||||||
Full Title: A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ... | |||||||||||||
Medical condition: advanced solid tumors | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) GB (GB - no longer in EU/EEA) NL (Trial now transitioned) DE (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) HU (Trial now transitioned) DK (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003862-41 | Sponsor Protocol Number: EORTC1825LCG | Start Date*: 2020-06-30 | |||||||||||
Sponsor Name:European Organisation for Research and Treatment of Cancer | |||||||||||||
Full Title: Activity of Lorlatinib based on ALK resistance mutations on blood in ALK positive NSCLC patients previously treated with 2nd generation ALK inhibitor | |||||||||||||
Medical condition: Non-small cell lung cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Completed) NL (Completed) FR (Completed) IT (Prematurely Ended) ES (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
